Earnings Call · Q4 FY2021·2022-03-29

Q4 21EPS +47.66%·Rev n/aQ3 21EPS +35.00%·Rev n/aQ2 21EPS +33.33%·Rev n/aQ1 21EPS +4.17%·Rev n/a⚠ consensus missing

Rani Therapeutics Holdings, Inc. RANI

Laurence Watts — Investor Relations or Corporate Communications

Talat Imran — Chief Executive Officer

Mir Hashim — Chief Scientific Officer

Svai Sanford — Chief Financial Officer

−8.5%1d on move date−6.7% vs SPY3d+5.1%5d+25.1%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more RANI calls or request research access.

More RANI calls Browse calls Request research access